2015
DOI: 10.1038/ncomms9116
|View full text |Cite
|
Sign up to set email alerts
|

Atomic basis for therapeutic activation of neuronal potassium channels

Abstract: Retigabine is a recently approved anticonvulsant that acts by potentiating neuronal M-current generated by KCNQ2–5 channels, interacting with a conserved Trp residue in the channel pore domain. Using unnatural amino-acid mutagenesis, we subtly altered the properties of this Trp to reveal specific chemical interactions required for retigabine action. Introduction of a non-natural isosteric H-bond-deficient Trp analogue abolishes channel potentiation, indicating that retigabine effects rely strongly on formation… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
89
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 71 publications
(95 citation statements)
references
References 52 publications
(82 reference statements)
5
89
1
Order By: Relevance
“…Whereas it was thought that the critical property of W was its hydrophobicity (Wuttke et al, 2005), recent studies have revealed that the ability of W to form H-bonds with the carbonyl/carbamate oxygen atom present in retigabine makes this contact critical (Kim et al, 2015). These studies suggest that the strength of the H-bond between retigabine and W236 determines the potency of retigabine.…”
Section: Discussionmentioning
confidence: 85%
“…Whereas it was thought that the critical property of W was its hydrophobicity (Wuttke et al, 2005), recent studies have revealed that the ability of W to form H-bonds with the carbonyl/carbamate oxygen atom present in retigabine makes this contact critical (Kim et al, 2015). These studies suggest that the strength of the H-bond between retigabine and W236 determines the potency of retigabine.…”
Section: Discussionmentioning
confidence: 85%
“…The Ind amino acid has seen limited use in structure-function studies for hydrogen bond testing (Lacroix et al, 2012; Pless et al, 2013, 2014; Kim et al, 2015; Zhang et al, 2015) and none thus far in structural or computational studies that would inform on its tolerance once encoded within a protein. For instance, it is not known if the Ind substitution would specifically limit hydrogen bonding at the indole nitrogen atom (the purpose for which it was designed) or could it also produce a new side-chain orientation that itself alters protein function.…”
Section: Resultsmentioning
confidence: 99%
“…During the past decade, K V 7 agonists have become a target for research seeking to design new therapies for neurological disorders. It was shown that the K V 7 agonist Retigabine, a clinically-used anticonvulsant, shifts the voltage dependence of activation of the heteromeric K V 7.2/K V 7.3 channel to more negative potentials, facilitating activation 66-70 . More recently, the heteromeric K V 7.2/K V 7.3 channel has a strong hysteretic behavior displaying, at least 2 modes, 71 analogs to what it has been discussed above.…”
Section: Introductionmentioning
confidence: 91%